Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
BERKELEY, Calif., Feb. 28, 2017 -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that Jim Neal, Chief Executive Officer, will present the company’s new strategic initiatives and value drivers at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 11:20 a.m. ET. The conference is being held at the Boston Marriott Copley Place hotel.
A live audio webcast of the presentation can be accessed in the Investors and Media section of XOMA's website at http://investors.xoma.com/events.cfm. An archived version of the webcast will be available via replay for 90 days following the presentation.
About XOMA Corporation
XOMA discovers and develops innovative antibody therapeutics. XOMA has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. There are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. XOMA continues to advance Phase 2 development activities for 358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism, particularly congenital hyperinsulinism and hypoglycemia after bariatric surgery. For more information, visit www.xoma.com.
CONTACTS: Investor contact: Luke Heagle Pure Communications +1 910-726-1372 [email protected] Media contact: Colin Sanford Pure Communications +1 415-946-1094 [email protected]
